ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.6086
0.00%
Brent Oil
83.76
0.00%
Bitcoin
67,220.11
0.21%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. KemPharm Inc (KMPH)

  7. KemPharm Inc (KMPH) Noticias

KMPH

KemPharm (KMPH)

KemPharm Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:KMPH
FechaHoraFuenteTítuloSímboloCompañía
29/04/202406:49Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KMPHKemPharm Inc
10/04/202415:23Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KMPHKemPharm Inc
10/04/202406:46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KMPHKemPharm Inc
08/04/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KMPHKemPharm Inc
03/04/202415:15Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:KMPHKemPharm Inc
01/04/202416:27Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:KMPHKemPharm Inc
30/06/202315:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KMPHKemPharm Inc
26/06/202315:20Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KMPHKemPharm Inc
15/05/202316:35Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:KMPHKemPharm Inc
15/05/202315:23Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KMPHKemPharm Inc
17/04/202315:26Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:KMPHKemPharm Inc
16/03/202305:02Edgar (US Regulatory)Proxy Soliciting Materials (revised) (prrn14a)NASDAQ:KMPHKemPharm Inc
15/03/202306:04Edgar (US Regulatory)Proxy Statment - Contested Solicitations (definitive) (defc14a)NASDAQ:KMPHKemPharm Inc
13/03/202315:30Edgar (US Regulatory)Proxy Soliciting Materials (revised) (prer14a)NASDAQ:KMPHKemPharm Inc
07/03/202316:31Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:KMPHKemPharm Inc
07/03/202316:28Edgar (US Regulatory)Annual Report (10-k)NASDAQ:KMPHKemPharm Inc
01/03/202306:43GlobeNewswire Inc.Zevra Therapeutics Begins Trading as ZVRANASDAQ:KMPHKemPharm Inc
28/02/202307:00GlobeNewswire Inc.Zevra Therapeutics Reiterates Commitment to Rare Disease Community as New Corporate Council Member of the National Organization for Rare Disorders (NORD)NASDAQ:KMPHKemPharm Inc
27/02/202315:30GlobeNewswire Inc.Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary ProxyNASDAQ:KMPHKemPharm Inc
27/02/202315:11Edgar (US Regulatory)Proxy Statement - Contested Solicitations (preliminary) (prec14a)NASDAQ:KMPHKemPharm Inc
27/02/202306:30GlobeNewswire Inc.Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 ResultsNASDAQ:KMPHKemPharm Inc
24/02/202306:30GlobeNewswire Inc.Zevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium™ 2023NASDAQ:KMPHKemPharm Inc
23/02/202306:30GlobeNewswire Inc.Zevra Therapeutics Announces Two Abstracts Accepted for Presentation at the 19th Annual WORLDSymposium™ 2023NASDAQ:KMPHKemPharm Inc
22/02/202307:50GlobeNewswire Inc.CORRECTION – KemPharm Announces Corporate Name Change to Zevra TherapeuticsNASDAQ:KMPHKemPharm Inc
22/02/202306:30GlobeNewswire Inc.KemPharm Announces Corporate Name Change to Zevra TherapeuticsNASDAQ:KMPHKemPharm Inc
31/01/202306:30GlobeNewswire Inc.KemPharm Enhances Senior Management TeamNASDAQ:KMPHKemPharm Inc
24/01/202306:30GlobeNewswire Inc.KemPharm Issues Letter to ShareholdersNASDAQ:KMPHKemPharm Inc
18/01/202306:30GlobeNewswire Inc.KemPharm Partners with the Hypersomnia Foundation to Support Sleep Disorder Research and AdvocacyNASDAQ:KMPHKemPharm Inc
11/01/202306:30GlobeNewswire Inc.KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A., to Chief Product Development OfficerNASDAQ:KMPHKemPharm Inc
09/01/202305:30GlobeNewswire Inc.KemPharm Announces Board and Leadership Changes to Support its Transformation into a Leading Rare Disease CompanyNASDAQ:KMPHKemPharm Inc
 Showing the most relevant articles for your search:NASDAQ:KMPH

Su Consulta Reciente

NASDAQ
LEMIX
LSE
53DH
Int.fin. 61
NASDAQ
FRIFFX
Nasdaq Dividend Achiever...
BIT
SNIOL5
Societe Generale Effekten
LATK
AMPLUSDT
Ampleforth
CSE
HZ.WT
Hertz Energy
AQSE
EMQQ.GB
HANetf ICAV
EU
C299S
C299S
AQSE
DUKE.GB
Duke Capital
LSE
76TU
Euro.bk. 24
EU
S425S
S425S
EU
BEAR00535409
Aspa Biond
NASDAQ
FEPZNX
Tactical Income Portfoli...
NASDAQ
CEGE
LSE
FE74
Ebrd 25
NASDAQ
FPANX
Future Path 529 College ...
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados